# Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia

> **NCT01429610** · PHASE2 · UNKNOWN · sponsor: **Asan Medical Center** · enrollment: 78 (actual)

## Conditions studied

- Precursor Cell Lymphoblastic Leukemia-Lymphoma

## Interventions

- **DRUG:** Rituximab+mVPDL

## Key facts

- **NCT ID:** NCT01429610
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-11
- **Primary completion:** 2018-01-01
- **Final completion:** 2019-01-01
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2018-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01429610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01429610, "Rituximab+mVPDL for CD20(+) Adult Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01429610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*